guidanc
strength driven us vs ex-u neither busi
broken trend guidanc consist messag
sustain high-teen growth expect
elev see concern around us guid
misguid may present buy opportun
strength larg us-driven deliv sale vs
mse beat driven us omnipod sale
mse lesser extent drug deliveri sale mse
ex-u omnipod slightli lighter vs mse result
reflect pt total omnipod momentum acceler diverg us
ex-u result pt sequenti momentum acceler us high-
teen momentum deceler ex-u despit deceler ex-u omnipod
growth cc growth broadli broken trend view
fact still surpass recent manag messag high-teen low-
growth broadli type payg-model metric continu advanc
rapidli make new patient start
total instal base total us volum go
pharmaci omnipod growth guidanc consist
expect preview cc growth guidanc vs today
although drug deliveri guid weaker view element
busi less import thought
guidanc exhibit result vs mse
us guidanc controversi guid us omnipod growth
midpoint us guid
impli slight y/i momentum acceler roughli bracket
street earn call center larg us omnipod
guid seem drawn investor interest impli growth
deceler second half let dig littl deeper
comp point harder guid
impli optic growth deceler us momentum slightli
acceler across year
sequenti guid impli q/q declin admittedli
heavier declin seen last also
reflect pt sequenti momentum deceler recal
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
manag guid pt momentum deceler
follow inflect yet proceed deliv beat
never guid us revenu growth quarter
histor despit deliv us growth
beat high end us quarterli guidanc
averag quarter similar beat would
lastli us growth rate sensit stock dynam seen ex-
us geographi see caus alarm
simpli put would sensibl manag guid
aggress guid aggress conserv
outlook year see us guidanc achiev across board
likelihood us omnipod upsid throughout year similar note
guidanc includ horizon impact similarli ex-u guidanc in-lin
expect high-teen growth appear achiev
although may see slightli greater quarter-to-quart volatil vs us
given distribut dynam acknowledg drug deliveri guidanc
weak view segment non-cor limit npv valu drug
deliveri materi drive margin anymor overal believ guidanc
reflect prudent conservat would view weak share buy
competit dynam earn call heard omnipod
experienc competit impact new aid system control-
iq ytd competit dynam consid includ control-iq
traction like launch ex-u within next quarter us
follow omnipod growth proven extrem durabl mdi
channel mdi patient add rose new patient add exit
impli tube-pump renew cycl newer product launch less
concern lastli note shown resili face
competit slim basal iq
profit mute expect written street margin like
need come given ramp second acton
manufactur line view guidanc flat gross margin vs
concern especi light recent concern around china
impact current omnipod manufactur capacity- product
facil base shenzhen view us capac expans posit
continu expect abl meet lrp target exit
product effici drive outsiz margin expans next year
continu reflect stabil net adjust model
drive ep oper margin expand
pt despit bp gm contract view impli pt
achiev flat model om vs
previous align model manag guidanc mid-teen
adjust ebitda margin overal encourag invest
channel ahead horizon
horizon commentari encourag horizon on-track launch
pivot trial see clinicaltri gov fulli enrol
patient age intend launch pediatr indic
manag emphas patient enthusiasm trial enrol posit
earli feedback possibl launch come slightli later year base
updat manag seek deploy model person control
algorithm follow pivot feedback sens timelin
would well within control concern
timelin slip beyond pivot data shown ada
expect qualit commentari pathway june
lrp continu look conserv bia remain posit
discuss past sever quarter see path
revenu clear moreov pathway greater profit
becom increasingli appar first year deliv
profit quarter remain confid manag abil meet lrp
target especi given market expans natur share captur
opportun embed payg shift pharmaci increas
opportun penetr popul model
sale remain confid guidanc mid-teen om
model om said believ much
optim reflect current valuat
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
dollar million except per share data
cash equival
prepaid expens current asset
accru expens current liabil
current portion long-term debt
current portion capit leas oblig
lt debt net discount
dollar million except per share data
non-cash interest expens
loss extinguish long-term debt
provis bad debt
net chang work capit
prepaid expens asset
account payabl accru expens current liabil
proce purchas short term invest
proce divestitur
net invest
princip payment capit leas
proce issuanc common stock
payment withhold tax connect
vest restrict stock unit
proce issuanc long-term debt
net issuanc cost
repay long-term debt
effect exchang rate chang cash
begin period
end period
net financ
long-term omnipod growth sustain
price target reect ev sale multipl base case
premium high growth smid cap peer
remain comfort
revenu growth omnipod continu
penetr insulin-intens diabet
popul given eas use form factor
access us pharmaci
path revenu clear
driven channel shift pharmaci
payg model ex us growth
expect horizon launch late
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ev/sal support dcf
ex us reacceler
underli growth payg model
shift pharmaci acceler us growth ap
competitor prove market expans
immateri omnipod growth greater
scale oper efcienc
pharmaci channel drive om
next year
ev/sal support dcf
us growth remain driven
shift pharmaci payg model
ex-u grow high-teen
mdi pediatr posit insul
omnipod ap competitor risk
remain path sale
gm clear like oor
horizon ap launch late
ev/sal support dcf
fail off-set competit headwind dash
 horizon adopt modest ap
timelin slip path greater protabl
becom less clear greater invest
requir support growth
shift pharmaci pay-as-you-go
distribut sustain ex us growth
path protabl improv us
horizon launch
china india
view explan region hierarchi
research highest favor quintil
ex-u growth re-acceler
greater abil drive manufactur
disclosur addit drug deliveri deal
